Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: Results from the CARE trial

Journal of Crohn's and Colitis

Volumn 7, Issue 1, 2013, Pages 34-43

  Louis, Edouard ^a   Löfberg, Robert ^b   Reinisch, Walter ^c   Camez, Anne ^d   Yang, Mei ^e   Pollack, Paul F ^e   Chen, Naijun ^e   Chao, Jingdong ^e   Mulani, Parvez M ^e  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d ABBOTT GMBH AND CO KG   (Germany)

^e ABBOTT LABORATORIES   (United States)

Author keywords

Adalimumab; Anti tumor necrosis factor; Crohn's disease; Indirect costs; Infliximab primary non responders; Infliximab na ve; Work productivity

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; CORTICOSTEROID; IMMUNOMODULATING AGENT;

ADULT; AGED; ARTICLE; COST CONTROL; CROHN DISEASE; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG COST; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HUMAN; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; SHORT INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE;

ACTIVITIES OF DAILY LIVING; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; EFFICIENCY; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WORK; YOUNG ADULT;

EID: 84872153521     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.02.017     Document Type: Article

References (25)

1. Lichtenstein G.R., Hanauer S.B., Sandborn W.J. Management of Crohn's disease in adults. Am J Gastroenterol 2009, 104:465-483.
2. Feagan B.G., Bala M., Yan S., Olson A., Hanauer S. Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol 2005, 39:390-395.
3. Blomqvist P., Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol 1997, 32:1134-1139.
4. Lichtenstein G.R., Yan S., Bala M., Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004, 99:91-96.
5. Loftus E.V., Schoedenfeld P., Sandborn W.J. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systemic review. Aliment Pharmacol Ther 2002, 16:51-60.
6. Vermeire S., van Assche G., Rutgeerts P. Review article: altering the natural history of Crohn's disease - evidence for and against current therapies. Aliment Pharmacol Ther 2007, 25:3-12.
7. Barreiro-de Acosta M., Domínguez-Muñoz J.E., de Vera MC Núñez-Pardo, Lozano-León A., Lorenzo A., Peña S. Relationship between clinical features of Crohn's disease and the risk of developing extraintestinal manifestations. Eur J Gastroenterol Hepatol 2007, 19:73-78.
8. Zisman T.L., Cohen R.D. Pharmacoeconomics and quality of life of current and emerging biologic therapy for inflammatory bowel disease. Curr Treat Options Gastroenterol 2007, 10:185-194.
9. Stark R., König H.H., Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics 2006, 24:797-814.
10. Feagan B.G., Vreeland M.G., Larson L.R., Bala M.V. Annual cost of care for Crohn's disease: a payor perspective. Am J Gastroenterol 2000, 95:1955-1960.
11. Yu A.P., Cabanilla L.A., Wu E.Q., Mulani P.M., Chao J. The costs of Crohn's disease in the United States and other Western countries: a systematic review. Curr Med Res Opin 2008, 24:319-328.
12. Mesterton J., Jönsson L., Almer S.H., Befrits R., Friis-Liby I., Lindgren S. Resource use and societal costs for Crohn's disease in Sweden. Inflamm Bowel Dis 2009, 15:1882-1890.
13. Feagan B.G., Reilly M.C., Gerlier L., Brabant Y., Brown M., Schreiber S. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study. Aliment Pharmacol Ther 2010, 31:1276-1285.
14. Binion D., Rutgeerts P., Van Assche G., Chen N., Chao J., Mulani P. Work productivity improvements in adalimumab-treated patients with moderate to severe ileocolonic Crohn's disease: the EXTEND trial. Am J Gastroenterol 2009, 104(Suppl. 3):S462.
15. Lichtiger S., Binion D.G., Wolf D.C., Present D.H., Bensimon A.G., Wu E., et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life, and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther 2010, 32:1228-1239.
16. Feagan B.G., Sandborn W.J., Wolf D.C., Coteur G., Purcaru O., Brabant Y., et al. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther 2011, 33:541-550.
17. Lofberg R., Louis E., Reinisch W., Robinson A.M., Kron M., Camez A., et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE. Inflamm Bowel Dis 2011, 18:1-9.
18. Irvine E., Zhou Q., Thompson A.K. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol 1996, 91:1571-1578.
19. Reilly M., Zbrozek A., Dukes E.M. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993, 4:353-365.
20. Reilly M.C., Gerlier L., Brabant Y., Brown M. Validity, reliability, and responsiveness of the Work Productivity and Activity Impairment questionnaire in Crohn's disease. Clin Ther 2008, 30:393-404.
21. Reilly M.C., Brown M.C., Brahant Y., Brown M. Defining the minimally important difference for WPAI: CD scores: What is a relevant impact on work productivity in active Crohn's disease?. Gut 2007, 56(Suppl. 3):A159.
22. European Commission Average gross annual earnings in industry and services: full-time employees in enterprises with 10 or more employees Accessed March 18, 2011, at. http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&plugin=1&language=en&pcode=tps00175.
23. Loftus E.V., Feagan B.G., Colombel J.F., Rubin D.T., Wu E.Q., Yu A.P., et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008, 103:3132-3141.
24. Feagan B.G., Yan S., Bala M., Bao W., Lichtenstein G.R. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003, 98:2232-2238.
25. Irvine E.J., Feagan B., Rochon J., Archambault A., Fedorak R.N., Groll A., et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994, 106:287-296.